PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational pharmaceutical company, today ...

More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has emerged victorious. As both companies reported Monday, a federal jury in the U ...

Guardant Health has continued a revenue increase as showcased in the last earnings report, growing 17% YoY. GH stock is part of a large industry that has high CAGR estimates, but investors are yet to ...

Guardant’s development-services segment, which accounts for roughly 20% of midcycle revenue, includes various other revenue from biopharmaceutical and medical institutions, such as regulatory approval ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce ...

(RTTNews) - Guardant Health Inc. (GH) and Hikma Pharmaceuticals have entered into an agreement to collaborate on the promotion of Guardant Health's range of liquid and tissue biopsy tests. The focus ...